Table 2.
Baseline characteristics of the RMN patients receiving JPQSF regimen.
| Characteristics | Value(n=15) |
|---|---|
| Age, mean (SD), y | 47.6(8.4) |
| Female, no. (%) | 5(33.3) |
| Urine protein excretion, mean (SD), g/24 h | 5.93(2.54) |
| Serum albumin, mean (SD), g/L | 23.88(3.28) |
| Estimated GFR, mean (SD), ml/min/1.73 m2 | 96.48(28.91) |
| Serum creatinine, mean (SD), umol/L | 80.33(26.42) |
| Total Cholesterol, mean (SD), mol/L | 7.82(2.23) |
| Triglycerides, median (IQR), mol/L | 3.10(1.53) |
| Histology stageb no. (%) | |
| I | 5(33.3) |
| II | 7(46.7) |
| I-II | 3(20.0) |
| Previous treatment no. (%) | |
| Prednisone + Cyclophosphamide | 6(40.0) |
| Prednisone +Cyclosporine | 7(46.7) |
| Tacrolimus | 2(13.3) |
Abbreviations. GFR: glomerular filtration rate.
aEstimated with the use of the Chronic Kidney Disease Epidemiology Collaboration creatinine equation.